True North Advisors’s GSK GSK Stock Holding History

True North Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,878	Closed	-$458K	–	221
2023 Q1	$458K	Sell	12,878 -5,174	-29%	-$181K	0.13%	133
2022 Q4	$634K	Hold	18,052	–	–	0.22%	99
2022 Q3	$531K	Buy	+18,052	New	+$684K	0.17%	109
2022 Q2	–	Sell	-18,070	Closed	-$983K	–	202
2022 Q1	$983K	Sell	18,070 -152	-0.8%	-$8.26K	0.26%	83
2021 Q4	$1M	Hold	18,222	–	–	0.17%	113
2021 Q3	$870K	Sell	18,222 -36	-0.2%	-$1.81K	0.17%	113
2021 Q2	$908K	Sell	18,258 -4	-0%	-$192	0.19%	102
2021 Q1	$814K	Sell	18,262 -298	-2%	-$13.5K	0.19%	97
2020 Q4	$853K	Sell	18,560 -3,568	-16%	-$164K	0.22%	87
2020 Q3	$1.04M	Buy	22,128 +332	+2%	+$16.6K	0.3%	71
2020 Q2	$1.11M	Buy	21,796 +15,551	+249%	+$798K	0.27%	74
2020 Q1	$295K	Buy	6,245 +91	+1%	+$4.85K	0.1%	99
2019 Q4	$361K	Buy	+6,154	New	+$342K	0.1%	78

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

True North Advisors's GSK Position: Q2 2023 in Review

True North Advisors sold out of GSK (GSK) in Q2 2023, closing a stake of 12,878 shares — an estimated $458K sold.

True North Advisors first reported a position in GSK in Q4 2019 and held it in 13 quarters. The position peaked at $1.11M in Q2 2020. 828 funds tracked by Wall St. Rank hold GSK as of Q2 2023.

True North Advisors reported no remaining GSK position as of Q2 2023 after selling out during the quarter.
True North Advisors sold 12,878 GSK shares in Q2 2023, an estimated $458K.
True North Advisors first reported a position in GSK in Q4 2019 and held it in 13 quarters.
True North Advisors's GSK position peaked at $1.11M in Q2 2020.
828 funds tracked by Wall St. Rank held GSK as of Q2 2023.

Based on True North Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.